• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PARP抑制剂在高级别浆液性输卵管卵巢癌的不同遗传背景中对免疫反应有不同调节作用。

PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma.

作者信息

Doro Pereira Luiza, Wielgos-Bonvallet Monica, Misirlioglu Selim, Khodadai-Jamayran Alireza, Jelinic Petar, Levine Douglas A

机构信息

Division of Gynecologic Oncology, Department of OB/GYN, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York.

Department of Pathology, Applied Bioinformatics Laboratories, NYU School of Medicine, New York, New York.

出版信息

Cancer Res Commun. 2025 Feb 1;5(2):339-348. doi: 10.1158/2767-9764.CRC-24-0515.

DOI:10.1158/2767-9764.CRC-24-0515
PMID:39851178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11836641/
Abstract

This work highlights how different PARPis, especially talazoparib, modulate immune-related gene expression in ovarian cancer cells, independent of the cGAS-STING pathway. These findings may improve our understanding of how different PARPis affect the immune system in various genetic backgrounds.

摘要

这项研究突出了不同的聚（ADP-核糖）聚合酶抑制剂（PARPis），尤其是他拉唑帕尼，如何在不依赖于环鸟苷酸-腺苷酸合成酶-干扰素基因刺激蛋白（cGAS-STING）途径的情况下，调节卵巢癌细胞中与免疫相关的基因表达。这些发现可能会增进我们对不同PARPis如何在各种基因背景下影响免疫系统的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/1bb880c99809/crc-24-0515_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/402768146dfd/crc-24-0515_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/15963e868bba/crc-24-0515_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/19689dd440ca/crc-24-0515_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/334ed5fb3be0/crc-24-0515_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/1bb880c99809/crc-24-0515_f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/402768146dfd/crc-24-0515_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/15963e868bba/crc-24-0515_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/19689dd440ca/crc-24-0515_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/334ed5fb3be0/crc-24-0515_f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2788/11836641/1bb880c99809/crc-24-0515_f5.jpg

相似文献

1
PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma.PARP抑制剂在高级别浆液性输卵管卵巢癌的不同遗传背景中对免疫反应有不同调节作用。
Cancer Res Commun. 2025 Feb 1;5(2):339-348. doi: 10.1158/2767-9764.CRC-24-0515.
2
Acquired Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.获得性启动子甲基化丢失导致高级别浆液性卵巢癌对 PARP 抑制剂耐药。
Cancer Res. 2021 Sep 15;81(18):4709-4722. doi: 10.1158/0008-5472.CAN-21-0774. Epub 2021 Jul 28.
3
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.CBL0137 抑制同源重组修复并增强高级别浆液性卵巢癌对 PARP 抑制剂的敏感性。
J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.
4
PARP Inhibitors Display Differential Efficacy in Models of Mutant High-Grade Serous Ovarian Cancer.多聚（ADP-核糖）聚合酶抑制剂在突变型高级别浆液性卵巢癌模型中显示出不同的疗效。
Int J Mol Sci. 2021 Aug 7;22(16):8506. doi: 10.3390/ijms22168506.
5
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.高级别浆液性卵巢癌的综合免疫基因组分析揭示了联合免疫疗法的潜在敏感性。
Front Immunol. 2024 Nov 28;15:1489235. doi: 10.3389/fimmu.2024.1489235. eCollection 2024.
6
Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant -Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor Rechallenge.多聚（ADP-核糖）聚合酶抑制剂奥拉帕利耐药-突变型卵巢癌细胞对 PARP 抑制剂再挑战显示出不同的敏感性。
Cells. 2024 Nov 7;13(22):1847. doi: 10.3390/cells13221847.
7
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.CHK1 抑制剂 Prexasertib 在高级别浆液性卵巢癌模型中具有单药活性，并增强对 PARP 抑制的敏感性。
Clin Cancer Res. 2019 Oct 15;25(20):6127-6140. doi: 10.1158/1078-0432.CCR-19-0448. Epub 2019 Aug 13.
8
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.整合临床分子数据以预测晚期卵巢癌患者在间歇性肿瘤细胞减灭术后对PARP抑制剂的疗效。
Gynecol Oncol. 2025 Apr;195:16-25. doi: 10.1016/j.ygyno.2025.02.016. Epub 2025 Mar 5.
9
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.一种3D功能检测方法的开发以及生物标志物的鉴定，这些生物标志物可预测高级别浆液性卵巢癌（HGSOC）患者对聚ADP核糖聚合酶抑制剂（PARPis）的反应：靶向治疗
J Transl Med. 2020 Nov 19;18(1):439. doi: 10.1186/s12967-020-02613-4.
10
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.ESMO 关于同源重组缺陷和 PARP 抑制剂在卵巢癌中获益的预测生物标志物检测的建议。
Ann Oncol. 2020 Dec;31(12):1606-1622. doi: 10.1016/j.annonc.2020.08.2102. Epub 2020 Sep 28.

本文引用的文献

1
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.avelumab 联合 talazoparib 治疗晚期实体瘤患者：JAVELIN PARP Medley 非随机对照试验。
JAMA Oncol. 2023 Jan 1;9(1):40-50. doi: 10.1001/jamaoncol.2022.5228.
2
Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors.砷化合物使同源重组功能正常的卵巢癌对PARP抑制剂敏感。
Cell Death Discov. 2021 Sep 22;7(1):259. doi: 10.1038/s41420-021-00638-2.
3
Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis.
PD-1/PD-L1 抑制剂在卵巢癌中的疗效：一项单臂荟萃分析。
J Ovarian Res. 2021 Aug 28;14(1):112. doi: 10.1186/s13048-021-00862-5.
4
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.PARP1 抑制剂通过 PARP1 捕获诱导的 DNA 损伤反应触发先天免疫。
Elife. 2020 Aug 26;9:e60637. doi: 10.7554/eLife.60637.
5
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.奥拉帕利联合度伐利尤单抗治疗种系 BRCA 突变转移性乳腺癌患者（MEDIOLA）：一项开放标签、多中心、1/2 期、篮子研究。
Lancet Oncol. 2020 Sep;21(9):1155-1164. doi: 10.1016/S1470-2045(20)30324-7. Epub 2020 Aug 6.
6
Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting.卵巢癌细胞系NIH-OVCAR3的特征分析以及基因组、转录组、蛋白质组和功能性DNA损伤反应生物标志物在治疗靶点方面的意义
Cancers (Basel). 2020 Jul 17;12(7):1939. doi: 10.3390/cancers12071939.
7
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.聚（ADP-核糖）聚合酶（PARP）抑制剂与免疫疗法联合用于实体瘤的治疗潜力
Front Oncol. 2020 Apr 28;10:570. doi: 10.3389/fonc.2020.00570. eCollection 2020.
8
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.奥拉帕利联合 PD-L1 抑制剂度伐利尤单抗治疗复发性卵巢癌：概念验证性 II 期研究。
Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12.
9
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.多聚（ADP-核糖）聚合酶抑制剂：奥拉帕利在卵巢癌及其他领域的应用。
Drugs R D. 2020 Jun;20(2):55-73. doi: 10.1007/s40268-020-00301-8.
10
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.尼拉帕利联合帕博利珠单抗治疗铂耐药复发性卵巢癌的单臂1/2期试验
JAMA Oncol. 2019 Aug 1;5(8):1141-1149. doi: 10.1001/jamaoncol.2019.1048.